Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2002

View Archived Issues

FDA requests additional animal study before lifting Vasomax clinical hold

Drug pipeline for bipolar disorder

MLN-2704 enters phase I in androgen-independent prostate cancer

Elan completes sale of Abelcet to Enzon

FDA panel recommends approval of rhBMP for open long bone fractures

Positive opinion for Levitra in E.U.

New inhibitors of GSK-3 and/or ROCK kinase under study at Vertex

AstraZeneca presents novel cannabinoid CB2 agonists as potential analgesic agents

Japan Energy and Sumitomo describe new immunomodulators for cancer and other disorders

Novel Src kinase inhibitors in early development at AstraZeneca

Series of vascular damaging agents and their use in cancer, arthritis, diabetes, etc.

Bayer claims Raf kinase inhibitors with utility in cancer

Inhibitor of novel cancer target is selectively cytotoxic to tumor cells

Positive opinion issued in E.U. for Hepsera

PX-478, the lead in a novel class of HIF-1 inhibitors with excellent antitumor activity

Antiangiogenic/antimetastatic peptide completes preclinical evaluation

Ethypharm and Conba enter into strategic alliance

NeuroSearch and GlaxoSmithKline target depression

Probiodrug and Synt:em to apply Pep:trans technology for the treatment of CNS diseases

Additional primary endpoint data released from phase III Aldurazyme study

New Backgrounder published -- Rhinovirus posted November 20, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...